Indication intelligence, analysis and sector perception

RegMed (RMI) Research Note: CRISPR Therapeutics (CRSP) Registered Direct Offering (RDO) $280 M offering priced at $71.50

February 13, 2024 10:10am

CRSP had closed +$6.34 at $76.44 and is down -$3.14 at $73.30

Has entered into an investment agreement for the sale of approximately $280 million of its common shares

To a select group of institutional investors in a registered direct offering, at a price per share of $71.50, representing a premium of greater than 10% to CRISPR Therapeutics’ 30-day volume-weighted average price.

The financing is expected to close on or about February 27, 2024, subject to customary closing conditions.

The Bottom Line: news was positive and stock was up – wham, bam – time to finance

The financing is being led by EcoR1 Capital and SR One with participation from existing and new investors and a new healthcare specialist investor.

Adds to last reported cash of $1.74 B, strengthens balance sheet with pro forma cash position $2.1 +billion

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

7 hours 18 min ago
RegMed Investors (RMi) Closing Bell: a month of up, downs; I thought were exercise

16 hours 8 min ago
RegMed Investors’ (RMi) pre-open: waiting and watching for the exhale of share pricing value

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.